Ceapro Inc. (CRPOF)
| Previous close | 0.1845 |
| Open | 0.1845 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.1845 - 0.1845 |
| 52-week range | 0.1150 - 0.4370 |
| Volume | |
| Avg. volume | 8,277 |
| Market cap | 14.445M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 23 May 2024 - 27 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCeapro Inc. Reports 2023 Financial Results and Operational Highlights
– 2023 marked by Ceapro’s achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Sales impacted (decreased by 49% from $18.8M in 2022 to $9.6M in 2023) due to re-organization associated with the spin-off of the consumer division of one major customer – Announced merger of equals with Aeter
- GlobeNewswire
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate comple
GlobeNewswireAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the “Transaction”) at their respective special meetings held today. The specific voting results were as follows: Aeterna shareholders approved the Transaction with the following voti
